MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML

Vegi, Naidu M.; Klappacher, Josef; Oswald, Franz; Mulaw, Medhanie A.; Mandoli, Amit; Thiel, Verena N.; Bamezai, Shiva; Feder, Kristin; Martens, Joost H. A.; Rawat, Vijay P. S.; Mandal, Tamoghna; Quintanilla-Martinez, Leticia; Spiekermann, Karsten; Hiddemann, Wolfgang; Döhner, Konstanze; Döhner, Hartmut; Stunnenberg, Hendrik G.; Feuring-Buske, Michaela und Buske, Christian (2016): MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML. In: Cell Reports, Vol. 16, No. 2: pp. 498-507

Abstract

Homeobox genes are known to be key factors in leukemogenesis. Although the TALE family homeodomain factor Meis1 has been linked to malignancy, a role for MEIS2 is less clear. Here, we demonstrate that MEIS2 is expressed at high levels in patients with AML1-ETO-positive acute myeloid leukemia and that growth of AML1-ETO-positive leukemia depends on MEIS2 expression. In mice, MEIS2 collaborates with AML1-ETO to induce acute myeloid leukemia. MEIS2 binds strongly to the Runt domain of AML1-ETO, indicating a direct interaction between these transcription factors. High expression of MEIS2 impairs repressive DNA binding of AML1-ETO, inducing increased expression of genes such as the druggable proto-oncogene YES1. Collectively, these data describe a pivotal role for MEIS2 in AML1-ETO-induced leukemia.

• Item Type: Journal article
• Faculties: Medicine
• Subjects: 600 Technology > 610 Medicine and health
• ISSN: 2211-1247
• Language: English